Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02111551 · ClinicalTrials.gov registry record · Phase 1
Phase I Nicotinic Agonist Treatment Trial for Autism
A Phase 1 study, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02111551: Clinical Trial Phase 1 study, sponsored by University of Colorado, Denver.
NCT02111551 is a Phase 1 study that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02111551, a Phase 1 study, was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study plans to learn more about whether a nicotine-like investigational new drug, DMXB-A \[3-(2,4-dimethoxybenzylidene) anabaseine\] may have positive effects on mental focus and may help us to find new types of treatment for autism spectrum disorder. Subjects will come in for a screening visit and three more drug visits. There will be at least one week between each drug visit to allow the drug to be eliminated from your system completely. During each drug visit subjects will receive either a placebo (a capsule that looks like medicine but is not real), 75 mg of DMXB-A, or 150 mg of DMXB-A. During the drug day vital signs and well being will be monitored by the study physician. Subjects will complete some paper and pencil tasks to test memory, attention, speed, and problem solving, some rating scales and questionnaires, and the study team will record brain wave patterns with an electroencephalogram (EEG) .
Interventions
- OTHER placebo
- DRUG DMXB-A 150 mg
- DRUG DMXB-A 75 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-06 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
Why NCT02111551 stopped before completion
NCT02111551 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT02111551 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02111551 about?
NCT02111551 is a clinical study titled "Phase I Nicotinic Agonist Treatment Trial for Autism". This study plans to learn more about whether a nicotine-like investigational new drug, DMXB-A \[3-(2,4-dimethoxybenzylidene) anabaseine\] may have positive effects on mental focus and may help us to find new types of treatment for autism spectrum disorder. Subjects will come in for a screening visit...
What is the current status of trial NCT02111551?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2015-06. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02111551?
The interventions under investigation include: placebo (OTHER), DMXB-A 150 mg (DRUG), DMXB-A 75 mg (DRUG).
Who is sponsoring clinical trial NCT02111551?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02111551's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia